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Abstract
Background: The main aim of this study was to evaluate Streptococcus pneumoniae carriage in a group of
school-aged children and adolescents with asthma because these results might indicate the theoretical risk of
invasive pneumococcal disease (IPD) of such patients and the potential protective efficacy of the 13-valent
pneumococcal conjugate vaccine (PCV13).
Methods: Oropharyngeal samples were obtained from 423 children with documented asthma (300 males,
70.9 %), and tested for the autolysin-A-encoding (lytA) and the wzg (cpsA) gene of S. pneumoniae by means
of real-time polymerase chain reaction.
Results: S. pneumoniae was identified in the swabs of 192 subjects (45.4 %): 48.4 % of whom were aged
<10 years, 46.9 % aged 10–14 years, and 4.7 % aged ≥15 years (p < 0.001). Carriage was significantly less
frequent among the children who had received recent antibiotic therapy (odds ratio [OR 0.41]; 95 %
confidence interval [95 % CI] 0.22–0.76). Multivariate analyses showed no association between carriage and
vaccination status, with ORs of 1.05 (95 % CI 0.70–1.58) for carriers of any pneumococcal serotype, 1.08 (95 %
CI 0.72–1.62) for carriers of any of the serotypes included in 7-valent pneumococcal conjugate vaccine (PCV7),
and 0.76 (95 % CI 0.45–1.28) for carriers of any of the six additional serotypes of PCV13. Serotypes 19 F, 4
and 9 V were the most frequently identified serotypes in vaccinated subjects.
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Conclusions: These results showed that carriage of S. pneumoniae is relatively common in all school-aged
children and adolescents with asthma, regardless of the severity of disease and the administration of PCV7 in
the first years of life. This highlights the problem of the duration of the protection against colonisation
provided by pneumococcal conjugate vaccine, and the importance of re-colonization by the same
pneumococcal serotypes included in the previously used vaccine.
Keywords: Asthma, Asthmatic children, Chronic respiratory disease, PCV7, PCV13, Pneumococcal colonisation,
Pneumococcal conjugate vaccine, Pulmonary disease, Streptococcus pneumoniae
Background
School-aged children and adolescents with asthma were
long thought to be not at any increased risk of invasive
pneumococcal disease (IPD), and were excluded from
the subjects considered for pneumococcal vaccine ad-
ministration [1]. However, some recent studies designed
to evaluate the possible relationship between asthma and
the incidence of IPD have highlighted the importance of
asthma in increasing the risk of pediatric IPD [2], and
official recommendations were modified to include
children aged 6–18 years (at least those treated with
high-dose corticosteroids) among the patients with
chronic underlying disease for whom pneumococcal vac-
cine should be strongly recommended [3].
The most recent recommendations indicate that
school-aged children and adolescents with asthma
should now receive the 23-valent polysaccharide vaccine
(PPSV23) rather than the 13-valent conjugate vaccine
(PCV13) [3]. This decision may be questioned because,
although it contains fewer pneumococcal serotypes than
PPSV23, PCV13 may offer greater protection as it is
more immunogenic [4] and has a significantly greater ef-
fect on pharyngeal carriage [5]. However, there are no
published data concerning PCV13 potential impact on
the incidence of IPD in asthmatic children.
Carriage is a prerequisite for the development of IPD
[6], and the different conjugate vaccines reduce the inci-
dence of IPD in vaccinated subjects mainly by affecting
nasopharyngeal colonisation with the pneumococcal se-
rotypes they contain [7]. Moreover, the reduced circula-
tion of these serotypes has positive effects also in
unvaccinated subjects who are significantly less colo-
nized than in the period before vaccine use [7]. As
evaluating pneumococcal colonisation is considered a
possible means of measuring the efficacy of conjugate
vaccine [8], the characteristics of carriage before vaccin-
ation may offer information regarding its potential
coverage and real efficacy.
The main aim of this study was to evaluate Streptococcus
pneumoniae carriage in a group of school-aged children
and adolescents with asthma because these results might
indicate the theoretical risk of IPD of such patients and the
potential protective efficacy of PCV13. Moreover, although
it was licensed in Italy in 2000, the heptavalent conjugate
vaccine (PCV7) was not widely used until 2009 even in
children with chronic severe underlying disease [9], and so
evaluating children born before this year may make it pos-
sible to compare carriage in both vaccinated and unvaccin-
ated asthmatic pediatric patients and thus measure the
long-term impact of PCV7.
Methods
Patient enrolment and swab collection
The protocol was approved by the Ethics Committees of
the seven hospitals (in Milan, Ethics Committee of
Milan Area B Fondazione IRCCS Ca’ Granda Ospedale
Maggiore Policlinico; in Pavia, Ethics Committee of
IRCCS Policlinico “S. Matteo” Foundation; in Garbagnate,
Ethics Commiitee of Milan Area C Niguarda Hospital; in
Padua, Ethics Committee of Padua Hospital; in Verona,
Ethics Committee of Verona province; in Rome, Ethics
Committee of IRCCS Bambino Gesù Hospital; in Naples,
Ethics Committee of Policlinico Hospital) whose Pediatric
Units enrolled asthmatic patients aged 6–17 years, regu-
larly attending their Respiratory Disease Centres between
January 2014 and December 2014 after written consent
from both parents had been collected and written assent
from children if aged ≥8 years had been obtained. The
characteristics of the asthma were evaluated on the basis
of the Global Initiative for Asthma criteria [10]. In all of
the patients, allergic sensitization was previously de-
termined by the evaluation of total IgE levels and IgE
antibodies to food allergens (cow’s milk, egg white,
and wheat), indoor allergens (house dust mite and cat
dander), and outdoor allergens (mixed grass and birch
pollen) by means of CAP-RAST FEIA (Pharmacia,
Freiburg, Germany). All of the patients were clinically
stable at the time of enrolment; patients with active
respiratory infection, those who had received anti-
biotic therapy during the previous 2 weeks, and those
with a chronic underlying disease other than asthma
were excluded. After enrolment, the clinical and la-
boratory data of each child for the previous 3 months
were retrieved from their clinical records and re-
corded in an electronic database specifically prepared
for the study.
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The patients’ pneumococcal vaccination status was
established by consulting the official vaccination chart
issued by the Vaccination Service of the Region in which
they lived. The pneumococcal immunisation schedule
recommended by the Italian Ministry of Health involves
three doses of PCV7 in the first year of life, or two in
the second year, or a single dose after the second year
until the fifth [11]. The patients were considered fully
vaccinated if one of these recommendations had been
fulfilled by the time of enrolment, and not fully vacci-
nated if they had started but not completed the vaccine
schedule: as the latter group consisted of only 1 % of the
enrolled subjects it was not compared with the groups
of fully vaccinated or unvaccinated children.
The oropharyngeal samples were obtained using an
ESwab kit containing a polypropylene screw-capped tube
filled with 1 mL of liquid Amies medium (Brescia,
Copan, Italy). The sampling was carried out by pressing
the tongue downward to the floor of the mouth with a
spatula, and swabbing both tonsillar arches and the pos-
terior nasopharynx without touching the sides of the
mouth. All of the swabs were immediately frozen at
−20 °C, and transported within a week to the central la-
boratory where they were processed within 2 h of
arrival.
Identification of S. pneumoniae
Bacterial genomic DNA was extracted from the samples
using a NucliSENS easyMAG automated extraction sys-
tem (BioMeriéux, Bagno a Ripoli, Florence, Italy), a
250 μL sample input and a generic protocol, and was
tested for the autolysin-A-encoding (lytA) and the wzg
(cpsA) gene of S. pneumoniae by means of real-time
polymerase chain reaction (PCR) as previously described
[12]. Level of detection of the test was 16 genome
copies, and each sample was tested in triplicate and
considered positive if at least two of the three tests
revealed the presence of both genes. In order to
maximise sensitivity, no internal amplification control
was used in the reaction, but there was an external
control. The real-time PCR-negative specimens were
also tested for the presence of an RNase P-encoding
gene in order to exclude PCR inhibition and DNA
extraction failure.
All of the positive cases were serotyped using primers
and probes designed on the basis of the GenBank database
sequences (www.ncbi.nlm.nih.gov) of serotypes 1, 3, 4, 5,
6A, 6B, 7 F, 9 V, 14, 18C, 19A, 19 F and 23 F (i.e. those in
the 13-valent pneumococcal conjugate vaccine, PCV13),
and synthesised by TIB Molbiol (Genoa, Italy) as pre-
viously described [12]. Analytical specificity was pre-
evaluated by means of computer-aided analyses using
Primer-blast (www.ncbi.nlm.nih.gov/tools/primer-blast)
and blast software (www.blast.ncbi.nlm.nih.gov/Blast.cgi)
in order to compare the sequences with all of the se-
quences listed under ‘bacteria’ and ‘homo sapiens’.
Statistical analysis
The groups were compared using the χ2 or Fisher’s exact
test as appropriate. The ordered categorical data were
compared using a Cochran-Armitage test for trend.
Multivariate odds ratios (ORs) and 95 % confidence in-
tervals (CIs) were calculated using unconditional mul-
tiple logistic regression models in order to measure the
associations between: i) pneumococcal vaccination and
pneumococcal carrier status; and ii) selected demo-
graphic and clinical characteristics and pneumococcal
carrier status. Adjustments were made for the covariates
defined a priori: i.e., age (i.e., 6–9 years, 10–14 years,
≥15 years), gender, ethnicity, the number of siblings, and
parental smoking habits. Stratified analyses were also
used for the two major age subgroups (<10 and 10–14
years). All of the analyses were two tailed, and p-values
of 0.05 or less were considered statistically significant.
All of the analyses were made using SAS version 9.2
(Cary, NC, USA).
Results
Table 1 shows the characteristics of the 423 enrolled
children with documented asthma (300 males, 70.9 %;
mean age ± standard deviation, 10.8 ± 2.8 years): 176
(41.6 %) were aged <10 years; 207 (48.9 %) aged 10–14
years, and 40 (9.5 %) aged ≥15 years. S. pneumoniae was
identified in the swabs of 192 subjects (45.4 %). Carriage
was more frequent in the younger subjects and declined
with age (48.4 % aged <10 years, 46.9 % aged 10–14
years and 4.7 % aged ≥15 years; p < 0.001), and signifi-
cantly more frequent among children born at term than
in those born pre-term (p = 0.005). There were no differ-
ences between carriers and non-carriers in terms of gen-
der, ethnicity, the number of siblings, parental smoking
habits, birth weight, exclusive breast feeding, allergic
sensitisation, or meningococcal or influenza vaccination.
Table 2 shows the associations between demographic
and clinical characteristics and pneumococcal carriage.
Carriage was not associated with parental smoking
habits (OR 1.36; 95 % CI, 0.90–2.07), systemic cortico-
steroid therapy in the previous 3 months (OR 1.03; 95 %
CI 0.59–1.81), the degree of severity of asthma (OR 1.02,
95 % CI 0.65–1.61 for moderate persistent asthma and
OR 0.90, 95 % CI 0.35–2.27 for severe persistent
asthma), or the occurrence of respiratory relapses in the
previous 3 months (OR 0.70; 95 % CI 0.45–1.10), but
was significantly less frequent among the children who
had received recent antibiotic therapy (OR 0.41; 95 % CI
0.22–0.76).
Table 3 shows the relationship between pneumococ-
cal vaccination status and pneumococcal carriage in
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the population as a whole and the two younger age
groups (there were too few vaccinated children in the
group aged ≥15 years). The proportions of carriers of
any pneumococcal serotype and any serotype included
in PCV7 were higher among the vaccinated subjects
(47.7 vs. 43.4 % among non-vaccinated subjects for
any serotype, and 45.1 vs. 39.9 %, respectively, for any
serotype included in PCV7), whereas the proportion
of carriers of the six additional serotypes included in
PCV13 were higher among the unvaccinated children
(18.9 %, as compared to 16.9 % among vaccinated
subjects). However, multivariate analyses showed that
there was no association between carriage and vaccin-
ation status: OR 1.05 (95 % CI 0.70–1.58) for carriers
Table 1 Main characteristics of 423 children and adolescents with asthma, by pneumococcal carriage
Characteristic All children (n = 423)
n (%)
Carriers (n = 192)
n (%)
Non-carriers (n = 231)
n (%)
p-value
Age
<10 176 (41.6) 93 (48.4) 83 (35.9)
10–14 207 (48.9) 90 (46.9) 117 (50.6)
≥15 40 (9.5) 9 (4.7) 31 (13.4) <0.001
Gender
Male 300 (70.9) 136 (70.8) 164 (71.0)
Female 123 (29.1) 56 (29.2) 67 (29.0) 0.97
Ethnicity
Caucasian 372 (87.9) 170 (88.5) 202 (87.5)
Non-Caucasian 51 (12.1) 22 (11.5) 29 (12.5) 0.73
No. of siblingsa
0 100 (23.8) 46 (24.2) 54 (23.5)
1 217 (51.7) 99 (52.1) 118 (52.3)
2 82 (19.5) 37 (19.5) 45 (19.6)
≥3 21 (5.0) 8 (4.2) 13 (5.6) 0.63
Parental smoking habit
Both non-smokers 276 (65.2) 119 (62.0) 157 (68.0)
At least one smoker 147 (34.8) 73 (38.0) 74 (32.0) 0.20
Gestational age (weeks)a
<37 49 (11.7) 13 (6.8) 36 (15.7)
≥37 370 (88.3) 177 (93.2) 193 (84.3) 0.005
Birth weight (g)a
<2500 39 (9.3) 13 (6.8) 26 (11.5)
≥2500 378 (90.7) 177 (93.2) 201 (88.5) 0.11
Exclusive breastfeedinga
No 139 (32.9) 56 (29.3) 83 (35.9)
Yes 283 (67.1) 135 (70.7) 148 (64.1) 0.15
Allergic sensitisation
No 59 (14.0) 26 (13.5) 33 (14.3)
Yes 364 (86.0) 166 (86.5) 198 (85.7) 0.83
Meningococcal vaccination
No 227 (53.7) 99 (51.6) 128 (55.4)
Yes 196 (46.3) 93 (48.4) 103 (44.6) 0.43
Flu vaccination during current seasona
No 351 (83.0) 162 (84.4) 189 (81.8)
Yes 72 (17.0) 30 (15.6) 42 (18.2) 0.49
aSome missing values
Bold data represent significant differences
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of any pneumococcal serotype, 1.08 (95 % CI 0.72–1.62)
for carriers of any serotype in PCV7, and 0.76 (95 % CI
0.45–1.28) for carriers of any of the six additional sero-
types in PCV13. The age group sub-analysis showed simi-
lar results without any differences between vaccinated and
unvaccinated subjects.
Table 4 shows the individual serotypes identified by
vaccination status. Only 10 children (four previously
vaccinated with PCV7 and six unvaccinated) were exclu-
sively colonised by serotypes not included in PCV13.
Among the vaccinated children colonised by S. pneumo-
niae, respectively 34.4, 44.1, and 17.2 % were carriers of
one, two or ≥3 PCV13 serotypes; the corresponding
figures among the unvaccinated patients were 29.2, 28.2
and 36.6 %. The use of PCV7 did not influence carriage
of one or two PCV13 serotypes, but the proportion of
PCV7-vaccinated children colonised with ≥3 PCV13 se-
rotypes was significantly lower than that of unvaccinated
children (OR 0.46; 95 % CI 0.23–0.91).
Serotypes 19 F, 4 and 9 V were the most frequently
identified serotypes in the vaccinated patients, and these
and serotype 5 were most frequently detected in the un-
vaccinated patients. None of the serotypes included in
PCV7 or PCV13 was associated with vaccination status.
Table 2 Association between demographic and clinical characteristics and pneumococcal carriage in children with asthma
Carriers (n = 192) Non-carriers (n = 231) Crude OR (95 % CI) OR (95 % CI)a
n (%) n (%)
Age
<10 93 (48.4) 83 (35.9) 1 (reference) 1 (reference)
10–14 90 (46.9) 117 (50.6) 0.69 (0.46–1.03) 0.69 (0.46–1.04)
≥15 9 (4.7) 31 (13.4) 0.26 (0.12–0.58) 0.25 (0.11–0.56)
Gender
Male 136 (70.8) 164 (71.0) 1 (reference) 1 (reference)
Female 56 (29.2) 67 (29.0) 1.01 (0.66–1.54) 0.94 (0.61–1.45)
Siblingsb
No 46 (24.2) 54 (23.5) 1 (reference) 1 (reference)
Yes 144 (75.8) 176 (76.5) 0.96 (0.61–1.51) 0.96 (0.61–1.53)
Parental smoking habit
Both non-smokers 119 (62.0) 157 (68.0) 1 (reference) 1 (reference)
At least one smoker 73 (38.0) 74 (32.0) 1.30 (0.87–1.95) 1.36 (0.90–2.07)
Asthma type
Intermittent 40 (20.8) 34 (14.7) 1 (reference) 1 (reference)
Mild, persistent 64 (33.3) 80 (34.6) 0.68 (0.39–1.19) 0.66 (0.37–1.17)
Moderate, persistent 79 (41.1) 103 (44.6) 0.65 (0.38–1.12) 0.67 (0.38–1.18)
Severe, persistent 9 (4.7) 14 (6.1) 0.55 (0.21–1.42) 0.59 (0.22–1.57)
Systemic corticesteroid therapy (previous 3 mos)b
No 158 (84.0) 194 (85.8) 1 (reference) 1 (reference)
Yes 30 (16.0) 32 (14.2) 1.15 (0.67–1.98) 1.03 (0.59–1.81)
Antibiotic therapy (previous 3 months)b
No 171 (90.5) 184 (81.8) 1 (reference) 1 (reference)
Yes 18 (9.5) 41 (18.2) 0.47 (0.26–0.85) 0.41 (0.22–0.76)
Respiratory relapses (previous 3 months)b
No 144 (76.2) 159 (70.3) 1 (reference) 1 (reference)
Yes 45 (23.8) 67 (29.7) 0.74 (0.48–1.15) 0.70 (0.45–1.10)
Asthma under controlb
No 33 (17.5) 54 (23.9) 1 (reference) 1 (reference)
Yes 156 (82.5) 172 (76.1) 1.48 (0.91–2.41) 1.41 (0.86–2.31)
aMultivariate model adjusted for age, gender, number of siblings, and parental smoking
bSome missing values. 95 % CI: 95 % confidence interval; OR: odds ratio
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Discussion
The findings of this study show that a considerable
number of school-aged children and adolescents with
asthma are colonised by S. pneumoniae. The highest
colonization rates were found among males and this is
not surprising because a strict association between
pneumococcal carriage and male gender has been
already reported by Cardozo et al. in healthy subjects of
the same age [13]. The global high rates of detection
may be explained by the fact that we used the most ac-
curate available methods. Respiratory secretions were
collected from the oropharynx which has been demon-
strated to be the most effective site for detecting S.
pneumoniae in older children and adults [14–16]. In a
recent study, it was shown that oropharyngeal sampling
appeared significantly more effective than nasopharyn-
geal sampling in identifying and characterizing pneumo-
coccal carrier status in adolescents [14]. Moreover, a
flocked nylon fibre tip was used because previous studies
have shown that this ensures the highest rate of detec-
tion of S. pneumoniae, particularly in comparison with
the more widely used Dacron and rayon swabs) [16]. S.
pneumoniae was identified by means of molecular
methods that, albeit with some exceptions [17], have
been found to be significantly more reliable than trad-
itional non-enriched cultures in routine practice [18].
Table 3 Relationship between pneumococcal vaccination status and pneumococcal carriage in children with asthma
Vaccinated with PCV7 (n = 195)
n (%)
Not vaccinated against
pneumococcus (n = 228) n (%)
Crude OR
(95 % CI)
OR (95 % CI)a
Pneumococcal carrier status
Any serotype
Non-carriers 102 (44.2) 129 (55.8) 1 (reference) 1 (reference)
Carriers 93 (48.4) 99 (51.6) 1.19 (0.81–1.74) 1.05 (0.70–1.58)
Serotypes in PCV7
Non-carriers 107 (43.8) 137 (56.2) 1 (reference) 1 (reference)
Carriers 88 (49.2) 91 (50.8) 1.24 (0.84–1.82) 1.08 (0.72–1.62)
Six additional serotypes in PCV13
Non-carriers 162 (46.7) 185 (53.3) 1 (reference) 1 (reference)
Carriers 33 (43.4) 43 (56.6) 0.88 (0.53–1.45) 0.76 (0.45–1.28)
Subgroup aged <10 years (n = 95) (n = 81)
Any serotype
Non-carriers 45 (54.2) 38 (45.8) 1 (reference) 1 (reference)
Carriers 50 (53.8) 43 (46.2) 0.98 (0.54–1.78) 1.01 (0.55–1.86)
Serotypes in PCV7
Non-carriers 49 (55.1) 40 (44.9) 1 (reference) 1 (reference)
Carriers 46 (52.9) 41 (47.1) 0.92 (0.51–1.66) 0.93 (0.51–1.72)
Six additional serotypes in PCV13
Non-carriers 74 (54.4) 62 (45.6) 1 (reference) 1 (reference)
Carriers 21 (52.5) 19 (47.5) 0.93 (0.46–1.88) 0.98 (0.47–2.03)
Subgroup aged 10–14 years (n = 87) (n = 120)
Any serotype
Non-carriers 47 (40.2) 70 (59.8) 1 (reference) 1 (reference)
Carriers 40 (44.4) 50 (55.6) 1.19 (0.68–2.08) 1.08 (0.61–1.94)
Serotypes in PCV7
Non-carriers 47 (38.8) 74 (61.2) 1 (reference) 1 (reference)
Carriers 40 (46.5) 46 (53.5) 1.37 (0.78–2.40) 1.22 (0.68–2.20)
Six additional serotypes in PCV13
Non-carriers 76 (43.7) 98 (56.3) 1 (reference) 1 (reference)
Carriers 11 (33.3) 22 (66.7) 0.65 (0.29–1.41) 0.54 (0.23–1.26)
95% CI 95 % confidence interval; OR odds ratio; PCV7 7-valent pneumococcal conjugate vaccine; PCV13 13-valent pneumococcal conjugate vaccine
aORs adjusted for age (as a continuous term), gender, ethnicity, number of siblings, and parental smoking
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Furthermore, to improve the detection of S. pneumoniae
without increasing the risk of false-positive results, both
the lytA and cpsA genes were amplified [19, 20]. This
permitted to avoid false-positive results because only S.
pneumoniae has both these genes, whereas different
streptococci that are not capsulated but that could col-
onies oropharynx possess only lytA gene but not cpsA
gene [19, 20].
It has been previously shown that pharyngeal bacterial
colonisation is associated with an increased risk of
asthma. Bisgaard et al., who cultured pharyngeal samples
taken from 321 healthy 1-year-olds followed up for
5 years found that those colonised by S. pneumoniae
and/or other bacterial respiratory pathogens such as
Haemophilus influenzae and Moraxella catarrhalis were
significantly more prone to develop persistent wheezing
(hazard ratio [HR] 2.40; 95 % CI 1.45–3.99), to experi-
ence severe wheezing exacerbations (HR 2.99; 95 % CI
1.66–5.33), and to be hospitalised because of wheezing
(HR 3.85; 95 % CI 1.90–7.99) [21]. Moreover, children
with asthma seem to have a primary immune response
defect that favours pneumococcal colonization. Larsen
et al. took peripheral blood mononuclear cells (PBMCs)
from infants aged 6 months, and stored them until the
children were 7 years old [22]; at this time, after stimula-
tion with Haemophilus influenzae, Moraxella catharralis
and S. pneumoniae, the PBMCs taken from the future
asthmatic subjects showed the aberrant production of
interleukin(IL)-5 (p = 0.008), IL-13 (p = 0.057), IL-17
(p = 0.001), and IL-10 (p = 0.028). The hypothesis that
colonization is favoured by a reduction in immune
system efficiency of subjects that later develop asthma
is further supported by the findings of Jung et al.
[23], who evaluated serotype-specific pneumococcal
antibody levels after the administration of PPSV23 and
found that the immune response to pneumococcal anti-
gens was defective in asthmatic young adults in compari-
son with healthy subjects. Furthermore, subjects with
atopic conditions other than asthma (i.e. atopic dermatitis,
allergic rhinitis, and hay fever) also have an impaired im-
mune response to S. pneumoniae [24]. Their underlying
immunological mechanisms are similar to those of asth-
matic children (i.e., a Th2-predominant immune milieu)
and they are significantly less able to produce specific anti-
body responses to PPSV23 [25], and they are at increased
risk of severe pneumococcal disease [26].
Table 4 Carriage of specific pneumococcal subtypes in children with asthma, by pneumococcal vaccination status
Vaccinated with PCV7,
n (%)
Not vaccinated with PCV7,
n (%)
Crude OR (95 % CI) OR (95 % CI)a
Total carriers 93 99
Carriers of serotypes not included in PCV13 4 (4.3) 6 (6.0) 0.84 (0.23–3.07) 0.97 (0.25–3.77)
Carriers of PCV13 serotypes
1 32 (34.4) 29 (29.2) 1.40 (0.80–2.47) 1.23 (0.69–2.21)
2 41 (44.1) 28 (28.2) 1.86 (1.08–3.21) 1.64 (0.93–2.89)
≥3 16 (17.2) 36 (36.6) 0.57 (0.30–1.08) 0.46 (0.23–0.91)
Carriers of different PCV13 serotypes
Serotype 1 1 (1.0) 2 (2.0) 0.58 (0.05–6.47) 0.56 (0.05–6.40)
Serotype 3 12 (13.0) 11 (11.1) 1.29 (0.56–3.00) 1.18 (0.50–2.80)
Serotype 4 26 (28.0) 39 (39.4) 0.75 (0.43–1.28) 0.62 (0.36–1.09)
Serotype 5 15 (16.1) 23 (23.2) 0.74 (0.38–1.47) 0.68 (0.33–1.38)
Serotype 6A 5 (5.4) 6 (6.1) 0.97 (0.29–3.24) 0.65 (0.18–2.40)
Serotype 6B 0 (0.0) 3 (3.0) NE NE
Serotype 7 F 2 (2.1) 4(4.0) 0.58 (0.10–3.20) 0.60 (0.10–3.49)
Serotype 9 V 18 (19.3) 22 (22.1) 0.95 (0.49–1.83) 0.95 (0.48–1.87)
Serotype 14 0 (0.0) 1 (1.0) NE NE
Serotype 18C 0 (0.0) 0 (0.0) NE NE
Serotype 19A 3 (3.2) 7 (7.1) 0.49 (0.13–1.94) 0.43 (0.11–1.77)
Serotype 19 F 83 (89.2) 84 (84.9) 1.27 (0.86–1.88) 1.13 (0.75–1.70)
Serotype 23 F 2 (2.1) 2 (2.0) 1.17 (0.16–8.40) 0.83 (0.11–6.26)
Reference category is non-carrier of corresponding serotypes
95% CI 95 % confidence interval; NE not estimable; OR odds ratio; PCV7 7-valent pneumococcal conjugate vaccine; PCV13 13-valent pneumococcal
conjugate vaccine
aORs adjusted for age (as a continuous term), gender, ethnicity, number of sibling, and parental smoking
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As expected, the prevalence of pneumococcal colon-
isation in our asthmatic subjects was strictly age-related
and was significantly lower in those who had recently re-
ceived antibiotic therapy. A progressive reduction in
pneumococcal colonisation with increasing age has been
repeatedly found in healthy children [27], including
school-aged children and adolescents [28], and can be
explained by the maturation of the immune system and
the progressive reduction of the role of factors such as
day-care attendance that can significantly enhance the
horizontal spread of pneumococcal strains.
Finally, carriage did not correlate with the severity of
asthma or variables such as the use of systemic cortico-
steroids or respiratory relapses in the period preceding
pharyngeal sampling (which were more frequent among
the patients with the severest asthma). If carriage is per
se a prerequisite for IPD, this seems to suggest that all
asthmatic children are at risk and that, although not offi-
cially recommended [3], all of them should undergo
pneumococcal vaccination, not just the severe cases
receiving long-term corticosteroid therapy. However,
further studies are needed with a large sample size of
children with severe asthma in order to identify fac-
tors that influence pneumococcal colonization in
these patients.
We did not find any statistically significant difference
in the carriage of particular pneumococcal serotypes
between the children previously vaccinated or not with
PCV7 in the population as a whole or in the subgroups
aged <10 or 10–14 years. Although only one sample
was taken from each child and we did not evaluate
pneumococcal colonisation over time, this seems to in-
dicate that the efficacy of PCV7 against colonisation
does not persist among children immunised in the first
years of life, at least not when vaccine uptake is rela-
tively low and more than 40 % of classmates remain un-
vaccinated. This finding, that confirms what has been
recently found in healthy school-aged children and ado-
lescents [28], is different from that reported by Le
Polain de Waroux et al. [29] and it is not easy to ex-
plain. Le Polain de Waroux et al., who studied nasopha-
ryngeal carriage in children vaccinated with PCV7,
found that this vaccine conferred reasonable protection
against acquisition of pneumococcal carriage of the 7
serotypes included in the vaccine for several years.
However, they studied children who have received the
vaccine 5–64 months after the last PCV7 dose, a period
shorter than that considered in this study. It can be
hypothesised that the antibody levels evoked in the first
years of life progressively decrease over time and after
several years, as in this study, become no longer ad-
equate to avoid colonisation. On the contrary, no role
at this regard had probably the lower number of PCV7
doses received by the children enrolled in this study.
Despite it was reported that 3 primary doses as in the
study by La Polain de Waroux et al. [29] could reduce
carriage more than 2 primary doses as in this study, the
differences were found borderline and statistically sig-
nificant only in one of the three comparative studies
that have evaluated the duration of protection against
carriage according to the number of PCV7 doses re-
ceived by the children [30]. Because each serotype has
different putative correlates of protection [31], it is
likely that those which need the highest concentrations
are those more frequently carried. We found that the
most commonly detected serotype was 19 F, which has
been reported to have a very high correlate of protec-
tion against IPD [32]. On the other hand, Simell et al.
[31] studied the associations between pneumococcal
nasopharyngeal carriage and the serum concentrations
of serotype-specific antibodies in toddlers 1 month after
they had been immunised with a 9-valent PCV, and
found that higher anti-serotype 14 and 19 F IgG and
anti-serotype 14 IgM correlated with a lower probabil-
ity of pneumococcal acquisition. However, the real rele-
vance of the pharyngeal re-colonization by the same
serotypes included in the previously used vaccine in
conditioning risk of disease in vaccinated children and
their households has to be established. Further studies
at this regard are needed.
About 95 % of the children colonised by S. pneumo-
niae carried at least one of the serotypes included in
PCV13, and only 10 cases were colonised only with
non-typeable serotypes. This seems to indicate that
PCV13 might be to be potentially efficacious in pre-
venting IPD in children with asthma and booster
doses have to be administered in order to avoid the
risk or recolonization. However, further studies are
needed to evaluate whether it can be administered
alone or in combination with PPV23 and whether
and when booster doses have to be periodically
administered.
A limitation of this study is represented by the absence
of a control group of healthy children and this does not
permit to evaluate whether children with asthma were
differently colonized in comparison to normal subjects
living in the same geographic area with limited pneumo-
coccal vaccination coverage.
Conclusions
The carriage of S. pneumoniae is common in all school-
aged children and adolescents with asthma, regardless of
the severity of the disease and the administration of
PCV7 in the first years of life. This highlights the prob-
lem of the duration of the protection against colonisa-
tion provided by pneumococcal conjugate vaccine, and
the role of pharyngeal recolonization from a clinical
point of view.
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